6.08
+0.06(+1.00%)
Currency In USD
| Previous Close | 6.02 |
| Open | 6.06 |
| Day High | 6.11 |
| Day Low | 5.98 |
| 52-Week High | 11.52 |
| 52-Week Low | 4.44 |
| Volume | 43,112 |
| Average Volume | 91,300 |
| Market Cap | 155.7M |
| PE | -4.44 |
| EPS | -1.37 |
| Moving Average 50 Days | 6.15 |
| Moving Average 200 Days | 7.61 |
| Change | 0.06 |
If you invested $1000 in Nuvectis Pharma, Inc. (NVCT) since IPO date, it would be worth $1,870.77 as of November 18, 2025 at a share price of $6.08. Whereas If you bought $1000 worth of Nuvectis Pharma, Inc. (NVCT) shares 2 years ago, it would be worth $733.41 as of November 18, 2025 at a share price of $6.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
GlobeNewswire Inc.
Nov 04, 2025 12:30 PM GMT
NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical n
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 16, 2025 12:00 PM GMT
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical n